<DOC>
	<DOCNO>NCT01937078</DOCNO>
	<brief_summary>Levodopa-induced dyskinesia common problem Parkinson 's disease ( PD ) . In particular , target non-dopaminergic system may option reduce dyskinesia without worsen motor symptom . One target may histamine . The central histaminergic system involve diverse biological function include thermoregulation , eat , sleep ; role motor activity suggest strong histaminergic innervation basal ganglion . Histamine H2 receptor highly express striatum , particularly GABAergic striatal-pallidal striatal-nigral pathway Histamine H2 stimulation modulate acetylcholine release . Previous study demonstrate block acetylcholine anticholinergic agent induce chorea . The investigator propose histamine H2 receptor stimulation decrease acetylcholine striatum increase activity direct striatal output pathway , key component neural mechanism underlie dyskinesia . The investigator hypothesise H2 antagonist would reduce activity direct striatopallidal pathway potentially reduce levodopa-induced chorea Famotidine also assess schizophrenia small case series treat schizophrenia , tolerability . Clinical experience thus suggest suitability use agent histamine H2 antagonist clinical study PD .</brief_summary>
	<brief_title>Famotidine Levodopa-induced Dyskinesia PD</brief_title>
	<detailed_description>The propose study compose multiple N -of 1 study perform randomized , double-blind , placebo-controlled multiple ( 4 ) crossover fashion . Twelve PD patient ( thus 12 N-of-1 trial ) levodopa-induced dyskinesia complete 4 treatment phase ; one phase 3 dos famotidine one placebo . The treatment dose : famotidine 40mg/day , 80mg/day , 120mg/day . The phase occur random order , subject receive treatment dos course study . After phase treatment ( 14 day ) , washout period ( 7 day , 10 half-lives famotidine ) follow crossover . The primary outcome change Unified Dyskinesia Rating Scale ( UDysRS ) placebo famotidine end treatment phase secondary outcome Movement Disorder Society Unified Parkinson Disease Rating Scale ( MDS-UPDRS ) part III IV , Clinical Global Impression ( CGI ) , Lang-Fahn activity daily live dyskinesia scale ( LFADLDS ) assessment adverse effect .</detailed_description>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Famotidine</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Eligible patient , male female , less 80 year age stable levodopa . Subjects must stable , bothersome dyskinesia MDSUPDRS score 2 great , item 4.2 . All antiparkinsonian medication must unchanged least one month prior study enrollment . Subjects may take amantadine stable dose least one month prior study onset prior surgery PD , Hoehn Yahr score 5 offmedication , history moderate severe renal impairment ( creatinine clearance &lt; 25 millilitre per minute , dementia ( defined Montreal Cognitive Scale &lt; 2518 , allergic reaction lactose , famotidine histamine H2 antagonist</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>